Accounts Receivable, after Allowance for Credit Loss, Current in USD of Regen BioPharma Inc from Q3 2016 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Regen BioPharma Inc quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and change rate from Q3 2016 to Q2 2025.
  • Regen BioPharma Inc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Jun 2025 was $177K, a 164% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Regen BioPharma Inc Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2025 $177K +$110K +164% 30 Jun 2025 10-Q 11 Aug 2025
Q1 2025 $150K +$110K +277% 31 Mar 2025 10-Q 28 May 2025
Q4 2024 $122K +$110K +894% 31 Dec 2024 10-Q 16 May 2025
Q3 2024 $94.9K +$94.9K 30 Sep 2024 10-Q 11 Aug 2025
Q2 2024 $67.1K +$10.6K +18.7% 30 Jun 2024 10-Q 13 Aug 2024
Q1 2024 $39.7K -$39.4K -49.8% 31 Mar 2024 10-Q 24 Apr 2024
Q4 2023 $12.3K -$119K -90.7% 31 Dec 2023 10-Q 19 Jan 2024
Q3 2023 $0 -$254K -100% 30 Sep 2023 10-K 13 May 2025
Q2 2023 $56.5K -$239K -80.9% 30 Jun 2023 10-Q 25 Jul 2023
Q1 2023 $79.1K -$189K -70.5% 31 Mar 2023 10-Q 18 Apr 2023
Q4 2022 $132K -$109K -45.3% 31 Dec 2022 10-Q 19 Jan 2023
Q3 2022 $254K +$41.1K +19.3% 30 Sep 2022 10-K 20 Nov 2023
Q2 2022 $295K +$110K +59.3% 30 Jun 2022 10-Q 22 Jul 2022
Q1 2022 $268K +$110K +69.6% 31 Mar 2022 10-Q 21 Apr 2022
Q4 2021 $241K +$110K +84.2% 31 Dec 2021 10-Q 20 Jan 2022
Q3 2021 $213K +$110K +107% 30 Sep 2021 10-K 15 Nov 2022
Q2 2021 $185K +$110K +146% 30 Jun 2021 10-Q/A 22 Dec 2021
Q1 2021 $158K +$82.6K +109% 31 Mar 2021 10-Q 18 Aug 2021
Q4 2020 $131K +$110K +534% 31 Dec 2020 10-Q 13 Aug 2021
Q3 2020 $103K +$32K +45% 30 Sep 2020 10-K 22 Dec 2021
Q2 2020 $75.5K +$32K +73.6% 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 $75.5K +$59.4K +371% 31 Mar 2020 10-Q 05 Aug 2021
Q4 2019 $20.6K +$20.6K 31 Dec 2019 10-Q 05 Aug 2021
Q3 2019 $71.2K +$71.2K 30 Sep 2019 10-Q 05 Aug 2021
Q2 2019 $43.5K +$43.5K 30 Jun 2019 10-Q 24 Oct 2019
Q1 2019 $16K +$16K 31 Mar 2019 10-Q 29 Aug 2019
Q4 2018 $0 $0 31 Dec 2018 10-Q 12 Feb 2019
Q3 2018 $0 $0 30 Sep 2018 10-K 21 Jun 2021
Q2 2018 $0 -$103K -100% 30 Jun 2018 10-Q 06 Aug 2018
Q1 2018 $0 -$83K -100% 31 Mar 2018 10-Q 14 May 2018
Q4 2017 $0 -$83K -100% 31 Dec 2017 10-Q 06 Feb 2018
Q3 2017 $0 -$83K -100% 30 Sep 2017 10-K 27 Dec 2018
Q2 2017 $103K 30 Jun 2017 10-Q 07 Aug 2017
Q1 2017 $83K 31 Mar 2017 10-Q 05 May 2017
Q4 2016 $83K 31 Dec 2016 10-Q 27 Jan 2017
Q3 2016 $83K 30 Sep 2016 10-Q 27 Jan 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.